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Abstract
Method validation is an important activity for pharmaceutical evaluations to ensure that
analytical methods are suitable for their intended use. With particular focus on active
ingredient and impurities, the implementation of different categories of method valida-
tion are explained for qualitative and quantitative methods. Detailed explanations with
example approaches are provided for the key aspects of method validation, namely
specificity, accuracy, linearity, limits of detection/quantitation, precision, robustness,
and method range. While all of the sections outlined for method validation are generally
applicable for a variety of techniques commonly used in pharmaceutical analysis (i.e.,
UV and HPLC instrumentation), focused attention is provided for examples that have
been implemented using high performance thin layer chromatographic techniques.
Keywords: method validation, pharmaceuticals, HPTLC, assay, active pharmaceutical
ingredient, impurities
1. Introduction
Method Validation (MV) is a development process undertaken to establish, within acceptable
statistical bounds, that an assessment procedure or method consistently yields a “true” result
both in “within laboratory” and “among laboratories” testing. Pharmaceutical product quality
assessments are focused on methods for the active pharmaceutical ingredient (API) and related
impurities. Being able to perform methods of analysis to assess product quality is critical in
law enforcement and regulating commerce. In addition, for new drug products, these quality
determinations are surrogate performance indicators for assuring the safety and efficacy of a
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pharmaceutical product. The safety and efficacy of a pharmaceutical product are established
with a “pivotal lot” production of the product and the characterization of this lot with well
validated methods with acceptable performance characteristics is critical to assure that future
production lots have the same quality characteristics as the “pivotal lot”, thereby assuring they
have equivalent safety and efficacy.
In the United States of America (USA), there are both private and public standards; the private
standards are created through a USA Food and Drug Administration (FDA) approval process
of industry method submissions that can be used for law enforcement, and public standards,
which are promulgated in the monographs of the United States Pharmacopeia (USP) [1], that
may be used in law enforcement or to support commercial agreements. The private standards,
which are not publicly available, are private agreements between the approving government
body and the submitting industry on the methods and standards to be used in law enforce-
ment. The method validation protocols for the establishment of private standards are provided
in the guidance of the “International Conference On Harmonisation Of Technical Require-
ments For Registration Of Pharmaceuticals For Human Use” (ICH) which have been incorpo-
rated into the laws and regulations in the European Union, Japan and the USA; these
procedures are required for the assessments of new drug entities [2]. The method validation
protocols for the establishment of monographs to support public standards are provided in
USP <1225> [3] and ICH Q2 [4]. Both protocols cite the same analytical performance character-
istics and test procedures except that the public standard must be able to be applied to all
legally marketed products containing the specific API whereas the private standard applies
only to the approved API in the specific product.
The analytical performance characteristics which must be assessed in both the ICH and USP
are Accuracy, Precision (both Repeatability and Intermediate in ICH), and Specificity. Detec-
tion Limit, Quantitation Limit, Linearity and Range depending on which attributes are to be
assessed. The USP presents the characteristics as noted below [3]:
“Category I — Analytical procedures for quantitation of major components of bulk drug
substances or active ingredients (including preservatives) in finished pharmaceutical products.
Category II — Analytical procedures for determination of impurities in bulk drug substances
or degradation compounds in finished pharmaceutical products. These procedures include
quantitative assays and limit tests.
Category III — Analytical procedures for determination of performance characteristics (e.g.,
dissolution, drug release, etc.).
Category IV— Identification tests.”
These can be categorized further into Assay procedures for Category I, Category II, impurity
determinations, and Category III (dissolution and drug release are different procedures for
preparing a solution of the API), all performance characteristics except Detection Limit must
be validated. For the Category II limit tests only the Specificity and Detection Limits must be
validated and for Category IV, Identification Tests, only the Specificity needs to be validated.
The following sections will provide approaches toward the various aspects of method
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validation. Although the approaches are generally applicable to common techniques used in
pharmaceutical analysis (such UV-VIS and HPLC quantifications), particular emphasis will be
placed on high performance thin layer chromatography (HPTLC) techniques.
2. Specificity
Specificity is the ability of a method to distinguish an analyte from all substances that are present
or likely to be present in test samples [3, 4]. When possible, these substances should include
future degradation products and other ingredients (i.e., excipients). An analytical procedure is
specific when placebo and impurity spots do not overlap partially with and are not buried under
the analyte spot. In addition, the calculated amount of analyte does not depend on the quantity
of other substances.
Various approaches are possible when evaluating method specificity [5–8]. Ideal demonstra-
tion of specificity for an HPTLC analytical procedure requires chromatographing simulta-
neously three types of samples: sample type 1 is the pure analyte or its reference standard,
sample type 2 is the analyte mixed with a representative blank and all likely impurities, and
sample type 3 is the representative blank mixed with all likely impurities. Likely impurities
include degradation products, reagents, intermediates, excipients, side products, and analyte
isomers. The mixtures can be created by spiking test samples (API substances or finished
products) or placebos with likely impurities.
In practice, the unavailability of one or more of these types of samples can pose a significant
challenge. In some cases, it is often difficult to know all likely impurities. There can be several
sample deficiency scenarios. If the pure analyte or its reference standard is not available,
demonstration of specificity can be quite challenging if not impossible. If a representative blank
is available, but some or all likely impurities are missing, the typical test sample is subjected to
stress testing environments. It should be noted however that stress testing is unlikely to
produce some analyte isomers, reagents, intermediates and side products. If a representative
blank is unavailable, but some likely impurities are available, spiking the typical test sample
with impurities can show that increasing impurities will not change analyte signal. In addition,
efforts should be made (perhaps by contacting the manufacturer), whenever possible, to create
a representative blank even if it’s not exactly in the same dosage form as the test sample. If
neither a representative blank nor impurity standards are available, the typical test sample is
subjected to stress testing to alleviate some of the deficiencies. Once again, the limitations of
stress testing should be acknowledged because it may not produce all likely impurities, it may
not account for impurities that are completely buried under the analyte signal, and it may not
indicate whether some excipients or impurities can react with the analyte.
In general, stress testing, impurity spiking, and peak-purity analysis are the common tools
used to address certain sample deficiencies. To demonstrate method specificity, validation
reports typically discuss several measures of performance. One measure of specificity is reso-
lution of the analyte spot relative to the closest non-analyte spot. For HPTLC, the resolution
should be a least 1 [5].
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Analyte peak purity is another measure of specificity that is typically reported. Often, analyte
peak purity in the analyte reference standard is compared to analyte peak purity in the other
test samples mentioned above. The analysis is performed by comparison of peak spectra at the
start, apex, and end of the analyte peak. Some authors use correlation coefficients [9] as a
measure of peak purity, and others rely on software algorithms that may involve Matrix
Algebra. It should be noted that while peak purity can detect the presence of some impurities
in the analyte peak, it does have some limitations. For example, peak-purity analysis does not
account for missing impurities that could overlap with the analyte peak, and it does not
account for impurities having a spectrum that is similar to that of the analyte. In addition,
peak-purity analysis is not applicable for detectors that do not register the entire analyte
spectrum for each time point.
A third measure of peak purity is an overlay of chromatograms. This measure is especially
useful for showing the analyte peak stability during impurity spiking or stress testing. For
example, the chromatograms of a finished pharmaceutical product, before and after acceler-
ated aging, can be overlaid to support method specificity.
3. Accuracy
A succinct definition of accuracy is “nearness to truth”. The ICH guidelines [4] provide the
following definition:
“The accuracy of an analytical procedure expresses the closeness of agreement between the
value which is accepted either as a conventional true value or an accepted reference value and
the value found.”
In other words, accuracy of a method represents the agreement between an expected value and
the value generated by the candidate method (the method value). Therefore, accuracy deter-
mination involves determining the expected value, finding the method value and calculating
the agreement between the two values [3, 4].
In pharmaceutical testing, accuracy is mainly relevant to quantitative methods, such as assay,
content uniformity, dissolution, and impurity quantitation. To determine the accuracy of a
quantitative HPTLC method, there are typically four major options, which differ mainly on
how the expected value is determined. Unfortunately, the most preferable options are not
always feasible due to the non-availability of appropriate reference standards or placebo
samples. For each option, we will explain how to determine the expected value and the
method value. Agreement between the two values will be addressed later.
3.1. Options for determining the expected value and the method value
3.1.1. Option 1 (using a certified reference standard)
The first option involves using a representative, certified reference standard. We say represen-
tative because the certified reference standard needs to have a chemical matrix that is the same
as the matrix of a typical unknown sample. So, if the method is intended for API quantitation
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in an API substance, the reference standard could contain only the API. However, if the
method is intended for finished product testing or for impurity quantitation in API substance,
the reference standard should contain the appropriate amount of all the substances typically
found in the finished product or API substance. The reference standard should be prepared by
an ISO certified reference material manufacturer.
3.1.1.1. Determining the accepted value
If a representative certified reference standard is available, the accepted value is the certified
amount of analyte (e.g. API) per given sample of the reference standard.
3.1.1.2. Determining the method value
To obtain the method value, at least nine reference standard solutions are prepared and tested
as if they were unknown samples, using the candidate HPTLC method. The average and
standard deviations of the results will represent the method value. The standard solutions
should contain the following analyte concentrations:
• The first three standard solutions should contain analyte concentrations between 50 and
90% of the analyte’s label claim (or quantitation limit for an impurity).
• The next three standard solutions should contain analyte concentrations between 90 and
110% of the analyte’s label claim.
• The last three standard solutions should contain analyte concentrations between 110 and
150% of the label.
• Due to the unavailability of representative certified reference standards for most pharma-
ceutical products, option 1 is rarely used in method validation.
3.1.2. Option 2 (Using a representative blank)
The second option involves using a representative blank, which means a substance or mixture
that contains all the chemical components of a typical unknown sample except the analyte. It is
important to note that the chemical composition of a representative blank depends on both the
analyte and the composition of a typical unknown. For assay, or content uniformity, the
representative blank is a placebo. For API quantitation in the API substance, the representative
blank is typically the solvent used to dissolve the standard. For impurity quantitation in an
API substance, the representative blank is typically the API substance. For impurity quantita-
tion in the finished product, the representative blank is a mixture of the placebo plus all the
APIs plus all the typical impurities. During testing, the representative blank should be treated
the same way as an unknown sample would be. Care must be taken so that only the absence of
analyte distinguishes the representative blank from a typical unknown sample.
3.1.2.1. Determining the accepted value
If a representative blank is available, at least nine samples are prepared by spiking the blank
with various amounts of analyte. The accepted value can be represented as the average and
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standard deviation of all the amounts of analyte spiked to the representative blank samples.
At least nine difference samples should be tested covering a minimum of three different
concentrations across the expected range of analyte concentration (50–150% of label claim or
impurity limit).
3.1.2.2. Determining the method value
Once the spiked blank samples are prepared, they can be analyzed in parallel using the
candidate HPTLC method. The average and standard deviation of the results (expressed in
the same unit as the accepted value) can represent the method value.
3.1.3. Option 3 (Using a reference method)
If options 1 and 2 are not feasible, a reference method can be used to determine the accuracy of
a candidate method. The reference method must be independent of the candidate method,
have been well validated with a stated accuracy, and have the same intended use as the
candidate method.
3.1.3.1. Determining the accepted value
To obtain the accepted value for option 3, the reference method can be used to test 6 or more
unknown samples. The average and standard deviation of the results will represent the
accepted value.
3.1.3.2. Determining the method value
To obtain the method value, each of the samples used to determine the accepted value is tested
using the candidate method. The average and standard deviation of the results will represent
the method value.
3.1.4. Option 4 (Using standard addition to unknown)
In lieu of option 3, method accuracy can be estimated using the standard addition method [10].
In this case the test sample is an unknown finished product or an API substance, whose
analyte amount has been predetermined using the candidate method.
3.1.4.1. Determining the accepted value
To obtain the accepted value for option 4, at least 6 or more stock solutions of unknown
samples should be prepared and tested per the candidate method. The average and standard
deviation of the results will represent the accepted value.
3.1.4.2. Determining the method value
To obtain the method value, each of the stock solutions used to determine the accepted value is
tested once again using the standard addition method [10]. So, each stock solution should have
its own standard addition curve with 5 or more data points. The average and standard
deviations of the absolute values of the x-intercepts will represent the method value.
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3.2. Agreement between expected and method values
Several calculation methods are used to determine the agreement between the expected and
method values. The percent recovery method is the simplest. It involves dividing the average
method value by the average expected value and multiplying the result by 100. Although this
method is considered acceptable in the ICH guidelines [3, 4], and it is found in many publica-
tions, it does not take the standard deviations into account.
One method that takes variation into account is the expanded uncertainty interval method
[11]. It involves combining the expected and method uncertainties to obtain the expanded
uncertainty, which is then compared to the difference between the average expected value
and the average method value. If the expanded uncertainty is greater or equal to the difference,
the candidate method is considered accurate.
A more statistically rigorous method to calculate accuracy is the t-test for two equal means
[12]. It can be performed using MS Excel or other statistical software, but it requires an
understanding of hypothesis testing. Interested readers can consult any general Statistics book
for more details on t-test and hypothesis testing.
The concept of accuracy profile, which is different from the concept of accuracy described herein,
is described by Shewiyo et al. It aims to describe method performance using a single statistic [13].
4. Linearity
Linearity evaluations demonstrate measurements from a test method are proportional to the
amount of analyte within a particular concentration range [3, 4]. Responses from samples
containing different amounts of analyte are obtained from the test method. Generally, a
minimum of five different concentrations should be used where multiple (i.e., ≥3) responses
are obtained at each analyte level. The method response (y-axis) is plotted as a function of the
analyte concentration (x-axis) for subsequent analysis with linear regression techniques, where
slope, intercept, and correlation coefficient are reported. The concentration range should cover
the upper and lower levels anticipated during an analysis.
In the following example, a graphical representation of a linear calibration model is demon-
strated, where the raw data is provided in Table 1 and Figure 1 shows the corresponding
linear regression curve.
[Concentration], w/v [Response], Instrument reading (triplicate results)
2 0.06, 0.06, 0.06
4 0.12, 0.12, 0.11
6 0.17, 0.17, 0.16
8 0.22, 0.23, 0.22
10 0.28, 0.28, 0.28
Table 1. Data to demonstrate a linear calibration model.
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However, a linear model may not be the best calibration fit for the data as is the case of the data
listed in Table 2, and plotted in Figure 2. When the linear model is applied to the data, the
resulting correlation coefficient (R2 = 0.98) is less than ideal.
Further examination of the data indicates that a polynomial fit can provide a better calibration
model from the data (Figure 3). It should be noted that most pharmaceutical analysis methods
commonly use a one-point standard during routine use of the method (after validation has
been established).
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Figure 1. Graphical representation of linear calibration model data.
Variable Data
[Concentration], w/v 1 2 3 4 5 6 7 8
[Response], Instrument reading 10 20 30 41 46 55 60 65
Table 2. Data to demonstrate a non-linear calibration model.
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Figure 2. Graphical representation of a less than ideal linear calibration model.
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If the analysis range for the method only requires concentrations from 1 to 4 (w/v), a linear
model for just that concentration range provides a r2 of 0.9994 (Figure 4) and would be easier
to implement in future analysis (note-an additional standard should be added within that
range during final validation).
5. Limits of detection/quantitation
Various options are possible for determining limits of detection (LOD) and limits of quantita-
tion (LOQ) [3, 4, 14, 15]. The section below will provide some key example approaches for tests
that generate instrument based responses.
y = -0.506x2 + 12.47x - 2.3393
R² = 0.9979
0
10
20
30
40
50
60
70
 )
g
ni
dae
R t
ne
m
urts
nI ( es
n
o
ps e
R
Concentration (w/v)
Figure 3. Graphical representation of polynomial approach to calibration model.
y = 10.3x - 0.5
R² = 0.9994
0
5
10
15
20
25
30
35
40
45
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
)
g
ni
dae
R t
ne
m
urts
nI(  es
n
o
pse
R
Concentration (w/v)
Figure 4. Graphical representation of the more linear range of the preceding polynomial calibration model.
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The signal to noise ratio can be used to determine both the LOD and LOQ, where responses are
obtained from blank and from an array of samples at lower concentrations. A ratio of signal
(from analyte samples) to noise (from blank) of 3 is an accepted concentration level for the LOD.
Likewise, a concentration level that provides a signal to noise of 10 can be used as the LOQ.
Another approach first involves the determination of the standard deviation of the response
and the slope of calibration (linearity) curve. Although other options are possible [3, 4, 14, 15],
the standard deviation of the response can be estimated from replicate injections from blank
samples or from the standard deviation of y-intercepts from multiple regression lines. Multi-
plying the ratio of the standard deviation of the responses to the slope of the curve by 3.3 or 10
provides the LOD or LOQ, respectively.
6. Precision
For an analytical method, precision is an assessment of the consistency of results obtained with
multiple measurements from the same sample [3, 4, 16]. There are three categories of precision
for an analytical method, namely repeatability, intermediate precision, and reproducibility,
which can be assessed through variations with different equipment, testing times (conducted
on different days), analysts, and/or laboratories.
Repeatability is often evaluated with replicate measurements of a sample on the same day in
the same laboratory, where the analyst and equipment are not changed. Intermediate precision
can be evaluated from replicate measurements of a sample within the same laboratory, but
with systematic variations with different analysts, times of analysis, and equipment (such as
different instruments). Reproducibility is commonly determined from replicate measurements
of the same sample but within different labs, which will inherently incorporate different
analysts, equipment, and time of analysis.
ICH Q2 provides several recommendations for number of replicates and concentration levels
for each of the three types of precision [4]. Recommended approaches for repeatability are at
least nine measurements that span the method’s range (such as three replicates for each of
three analyte levels) or at least six measurements at the target analyte level. ICH Q2 does not
specify a minimum number of samples for intermediate precision and reproducibility but
encourages that the effects of variables (i.e., analysts, days, instruments) be systematically
evaluated. The following section will provide possible approaches for evaluating repeatability
and intermediate precision, followed by references for examples for reproducibility will be
provided.
To perform the appropriate precision assessments, the following equations are indicated [16]
and will be used for further development of subsequent examples. The average (x) of n
replicates is provided in Eq. (1),
x ¼
Pn
i¼1
xi
n
(1)
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where xi represents the individual replicates measurements. The standard deviation (s) of a
data set can be determined through Eq. (2),
s ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiPn
i¼1
xi  xð Þ
2
n 1ð Þ
vuuut
(2)
and the % relative standard deviation (%RSD) is provided in Eq. (3).
%RSD ¼ 100
s
x
 
(3)
The %RSD is often used in method validation assessments because it normalizes the standard
deviation to the average.
From Eqs. (1)–(3), an evaluation of repeatability can be determined. In the following example,
assume that an analyst has performed six replicate analysis (within the same laboratory) from
a method capable of quantifying the amount of active ingredient in a pharmaceutical product
in units of % label claim (assay) and obtained the following results (102.1%, 100.5%, 98.2%,
99.1%, 101.8%, 99.8%). Using Eqs. (1)–(3), the average (x), standard deviation (s), and %RSD
would be 100.25%, 1.52%, and 1.52%, respectively, where s (or more commonly %RSD), is a
measure of method repeatability.
Intermediate precision involves an evaluation of variations “within runs” and “between runs”
[17]. Consider the data in Table 3 containing replicate runs (n = 3, indexed with j) obtained on
each of multiple days (p = 5, indexed with i), where each day used a different analyst with
separate solution preparations but using the samemethod as above for the repeatability analysis.
With each entry in the data representing a separate xij, the repeatability or within-run standard
deviation (days) can be determined using Eq. (4), where xi is provided in Eq. (5).
sr ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Pp
i¼1
Pn
j¼1
xij  xi
 2
p n 1ð Þ
vuuuut
(4)
n = 3(j)/p = 5(i) Day 1 Day 2 Day 3 Day 4 Day 5
Replicate 1 102.2 98.7 99.3 101.9 102.1
Replicate 2 100.3 101.8 98.1 100.1 101.4
Replicate 3 99.9 102.3 98.7 99.1 101.2
xi 100.8 100.9 98.7 100.4 101.6
x 100.5
Table 3. Example data for intermediate precision determination.
Method Validation Approaches for Pharmaceutical Assessments – Highlights with High Performance Thin…
http://dx.doi.org/10.5772/intechopen.71765
153
xi ¼
Pn
j¼1
xij
n
(5)
The between-run standard deviation (days) can be calculated with Eq. (6), where x is provided
in Eq. (7).
sB ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Pp
i¼1
xi  x
 2
p 1

s2r
n
vuuut
(6)
x ¼
Pp
i¼1
Pn
j¼1
xij
pn
(7)
Subsequently, the intermediate precision standard deviation can be calculated with Eq. (8).
sIP ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffi
s2r  s
2
B
q
(8)
From the data presented in Table 3 and using Eqs. (4)–(8) [17], the standard deviations for
repeatability (within-run), between-run, and intermediate precision are calculated as 1.26, 0.80,
and 1.49, respectively.
Evaluations for reproducibility utilize interlaboratory trials, and are commonly employed
when a procedure requires further standardization for use among a more extended array of
laboratories. ISO 5725 [18] provides the necessary approach andmanagement structure needed
to properly plan, conduct, and interpret the results of an interlaboratory trial that will involve
multiple laboratories conducting replicate analysis of a sample(s) at a particular analyte level(s).
Approaches are provided to graphically (Mandel’s statistics) and quantitatively (Cochran/
Grubb) identify outliers so that the most accurate assessments of repeatability and reproducibil-
ity variance (standard deviations) are possible. The calculations involved in these types of trials
are fairly extensive. Several examples are provided within ISO 5725, and Vander Heyden et al.
provides a detailed example for an interlaboratory trial for an HPLC procedure [19].
Overall, desired levels for precision for pharmaceutical analysis are commonly on the order of
~2%RSD.However, different ranges can be necessary depending on the concentration level of the
analyte (i.e., higher levels of %RSD can be allowed as the analyte concentration decreases) [17].
7. Robustness
Robustness is a measure of how much a method is impacted by deliberate (small) changes in
method conditions [3, 4]. The following are a listing of the types of parameters that can be
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evaluated to assess method robustness; solution stability (to heat and or time), extraction
conditions during sample preparation (time, temperature, mechanical shaking time, sonication
time), type of filters used during final standard/sample preparation, minor adjustments in
mobile phase composition, and adjustments in other chromatographic conditions (flow rate,
different suppliers of columns, temperature). Commonly, robustness is evaluated during the
development stages of the method.
An approach for evaluating robustness could be to compare an analysis using the primary
method compared to an analysis where a certain parameter is adjusted. Depending on the
method and sample type, adjustments in parameters that generate less than ~2% difference
relative to the primary method can provide a reasonable measure of how sensitive the method
is to various types of adjustments. During the development of the method for example, a study
could be conducted to evaluate the sensitivity of the method on the type of filter by comparing
the results from a sample solution that was centrifuged (without filtration) to those filtered
with different filter types (PTFE, PVDF, nylon) from different manufacturers. Solution stability
could be evaluated by comparing results from freshly prepared solutions compared to the
same solutions stored at room temperature over several days.
There are a variety of approaches that can be incorporated to evaluate method robustness.
Dejaegher and Vander Heyden provide an extensive review for a variety of approaches to
systematically evaluate method robustness (ruggedness) [20].
8. Range
The range of the method corresponds to the lower and upper analyte concentration where
satisfactory levels of linearity, precision, and accuracy have been achieved during the method
validation process. The range is indicated in the same units as that of the results obtained from
the method.
For analysis of pharmaceutical products [3, 4], the following ranges (in percentage relative to
the target level) are often required for the respective types of tests; assay (80–120%), content
uniformity (approximately 70–130%), impurities (approximately 50–120% of the acceptance
limit), dissolution ( 20% of the required range).
9. Application with HPTLC techniques
High-performance thin layer chromatography (HPTLC), an extension of TLC, is a robust,
simple, rapid, and efficient tool in quantitative and qualitative analysis of compounds [21],
and a variety of applications can be found in the literature [22–29]. In this section an overview
of applications of HPTLC in typical pharmaceutical testing protocol is highlighted with exam-
ples. HPTLC is one of the sophisticated instrumental techniques based on the full capabilities
of thin layer chromatography. The advantages of automation, scanning, full optimization,
Method Validation Approaches for Pharmaceutical Assessments – Highlights with High Performance Thin…
http://dx.doi.org/10.5772/intechopen.71765
155
selective detection principle, minimum sample preparation, hyphenation, and so on enable it
to be a powerful analytical tool for chromatographic information of complex mixtures of
pharmaceuticals, natural products, clinical samples, and food stuffs [21]. HPTLC is one of the
ideal TLC technique for the analytical purposes because of its increased accuracy, reproduc-
ibility, and ability to document the results, compared with standard TLC. Because of this,
HPTLC technologies are also the most appropriate TLC technique for conformity with GMPs
[30].
9.1. Identification test
In a pharmaceutical testing protocol, identification tests are intended to ensure the identity of
an analyte in an API or finished pharmaceutical product sample. This is normally achieved by
comparison of a chromatographic behavior of unknown sample to that of a reference standard.
The identity of the test substance is confirmed if the migration distance of the test substance
matches that of the reference substance. Thin layer chromatography experiments are among
the key identity tests in most pharmacopeia monographs. Pharmacopeia standards are typi-
cally used by industry as a basis for meeting QC requirements and current good manufactur-
ing practices (cGMPs). Many identification tests in the major pharmacopeia (e.g., USP, Ph. Int.,
and Ph. Eur. [1, 31, 32]) use planar chromatography (TLC), however HPTLC is a superior
technology. Figure 5 below represent a typical densitogram obtained in the identification of
sulfamethoxazole (SMX) and trimethoprim (TPM). In this example, the migration distances are
0.35 and 0.90 for TMP and SMX respectively.
Figure 5. An example of overlaid densitogram for identification of sample 1 and a reference 2 containing sulfamethoxa-
zole (SMX) and trimethoprim (TPM). Conditions Mobile Phase: (Methanol: Ethyl Acetate: Toluene 6: 9:15 v/v) Detection
Wavelength: 275 nm and Application Volume: 5 μl and aluminum plates precoated with silica gel 60 F254 as the
stationary phase.
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9.2. Assay content determination
A secondmost important critical quality attribute for pharmaceutical products testing is assay or
determination of content. The procedure intended to measure the analyte present in a sample. In
this context, the assay represents a quantitative measurement of the major component(s) in the
drug substance. This is done by comparing the area under the peak of test substance to that of
reference standard material. For a drug product, containing paracetamol an overlaid
densitogram is presented in Figure 6. Similar validation characteristics also apply when assaying
for the active or other selected component(s). The same validation characteristics may also apply
to assays associated with other analytical procedures (e.g., dissolution) [33].
9.3. Impurities and related substances
The principal requirement is that an analytical method for assessing impurities should be a
stability indicating and meeting specificity criteria described in Section 2 above. Stability indicat-
ing method (SIM) is defined as a validated analytical procedure that accurately and precisely
measures the active ingredients (drug substance or drug product) free from process impurities,
excipients and degradation products. This can be demonstrated by forced degradation study of
the drug substance and subjecting the resultant solution to the chromatographic conditions [34].
Testing for impurities can be either a quantitative test or a limit test for the impurity in a
sample. Either test is intended to accurately reflect the purity characteristics of the sample.
Quantitative tests for impurities are meant to quantify the exact amount of impurity. This is
Figure 6. An example of overlaid densitograms for assay of paracetamol in sample tracks 2, 3, 5, 8 and 9, and a reference
in tracks 1, 4 and 7. Conditions: Mobile Phase: Acetone; Methanol; Toluene: 6:6:16 v/v/v acidified with three drops of
Glacial Acetic Acid, Detection Wavelength: 274 nm, Application Volume: 5 μl and aluminum plates precoated with silica
gel 60 F254 as the stationary phase.
Method Validation Approaches for Pharmaceutical Assessments – Highlights with High Performance Thin…
http://dx.doi.org/10.5772/intechopen.71765
157
done by comparing the response from a single or multi-level calibration curve. Whereas the
limit test is an estimative test where the impurity is controlled not to exceed certain limit. In
this case an impurity standard is prepared at the control level and compared to the response
from the sample (which should not exceed this level).
With the improved resolution powers of HPTLC (enhanced by reduced particle sizes), it is
possible to perform both tests by using HPTLC. In the literature, there are many stability
indicating method for various drug substances for example pseudoephedrine and cetirizine
in pharmaceutical formulations [35], clopidogrel bisulphate [36] timolol maleate [37] simulta-
neous determination of ezetimibe and simvastatin [38], piroxicam [39], and estradiol [40].
9.4. Dissolution testing
Dissolution testing is a performance characterizing test and a requirement for all solid oral
dosage forms and is used in all phases of development for product release and stability testing
[41–43]. It is a key analytical test used for detecting physical changes in an active pharmaceu-
tical ingredient (API) and in the formulated product. It is a multi-unit test and multi-point
sampling, making it very tedious. HPTLC offers a multi-channel capability where a total of 18–
25 samples can be applied on one plate in form of bands and analyzed simultaneously. One lot
of a product will require 6 units (tested in duplicate), plus calibrators (in triplicates at single or
multiple levels). HPTLC methods have been successfully deployed for monitoring dissolution
profile of diclofenac and acetaminophen [44], and the stability of rifampicin in dissolution
medium in presence of isoniazid [45].
9.5. Content uniformity
The test for Content Uniformity (CU) is the assay of the individual content of drug substance(s)
in a number of individual dosage units to determine whether the individual contents are
within the set limits [46]. Multiple capsules or tablets are selected at random and each are
analyzed to determine the active ingredient in each capsule or tablet. The performance effi-
ciency of this method can benefit from the HPTLC multi-channel capabilities. HPTLC has been
successful applied in content uniformity of atorvastatin calcium tablets [47], diazepam tablets
[48], diosgenin and levodopa [49], nicorandil tablets [50] and rosiglitazone in tablets [51]. All of
these HPTLC method examples provide a faster, more cost efficient approach to quantitative
testing for routine analysis.
10. Conclusions
Classic method validations for pharmaceuticals involve techniques such as UV-VIS, TLC, and
HPLC. This chapter highlights different examples with High Performance Thin Layer Chro-
matography (HPTLC). General approaches are provided for method validation, as applicable
to pharmaceutical assessments, outlined for each of the key aspects (i.e., specificity, accuracy,
linearity, limits of detection/quantitation, precision, robustness, and range). Although classical
application of pharmaceutical method validation uses techniques such as UV-VIS or HPLC,
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important examples are provided using HPTLC techniques that provide high accuracy/preci-
sion with minimal use of reagents and other resources.
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